Labcorp and Hawthorne Effect are pleased to announce a strategic collaboration to advance decentralized clinical trial capabilities for pharma, biotech and medical device sponsors seeking to increase patient diversity and inclusion, decrease site burden, and accelerate enrollment and clinical study timelines. Through the collaboration, Labcorp and Hawthorne Effect aim to combine their services and create new, differentiated service offerings to support decentralized clinical trials. Hawthorne Effect’s comprehensive digital platform allows complex study visits and clinical data collection to be conducted seamlessly in the patient home or community and has been demonstrated to increase diverse patient participation, improve quality, completeness and timeliness of trial data, and accelerate trial timelines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LH:
- Labcorp initiated with an Equal Weight at Barclays
- SomaLogic corrects ‘Madryn Asset Management’s misleading disclosure’
- SomaLogic shareholder says company ran ‘incomplete’ review of alternatives
- Labcorp and Legacy Health Finalize Comprehensive Laboratory Relationship
- Labcorp price target raised to $261 from $259 at JPMorgan